Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Biomarker Validation for Genomic Assays
Assay Developers Put Their Tests to the Test and Demonstrate the Clinical Utility of Genomic Biomarkers
For full access to this article login to GEN Select now.
Capitalizing on Fragment-Based Discovery
Computational and Medicinal Chemists Are Joining Forces to Turn Hits into Leads
- Fragment-based drug discovery is gaining momentum as an efficient strategy to find and optimize leads. The technology first identifies small chemical fragments that bind weakly, yet efficiently, to the target, and then grows or combines them to produce a lead with a higher affinity. Fragment-based discovery differs from ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.